Month: 2024-09

TEL AVIV, IL, Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - A2Z Cust2Mate Solutions Corp. ("A2Z") (NASDAQ:AZ)(FRA - WKN:A3CSQ), a global leader in innovative technology solutions, today announced it has signed global framework agreements with Nayax Capital, ("Nayax Capital"), whereby Nayax Capital will enable financing for the sale or lease of Cust2Mate smart carts enabled with Nayax’s complete solution.This announcement is further to the company’s press release on September 10, 2024 announcing the formation of a joint venture with Nayax Ltd. to mutually promote the sales of A2Z Cust2Mate’s smart cart solution integrated with Nayax’s payment solution for on-cart payments. The joint venture announcement can be read here.Under the terms of the framework agreements, Nayax Capital will enable retailers to pay or lease the Cust2Mate smart carts that are sold as part of a comprehensive solution, which includes Nayax’s payment, management and loyalty solution, in monthly installments. The framework agreements cover the A2Z Cust2Mate’s smart carts, charging solutions, and IT infrastructure upgrades, as needed, for customers around the world including Europe, North America and Latin America. Any financing extended is subject to individual terms and conditions and approval by Nayax Capital and is non-recourse to A2Z.Gadi Graus, CEO of A2Z, stated, “We have teamed up with Nayax Capital to help merchants grow by making it easier for retailers around the globe to adopt our smart cart solution. With a readily available financing option, approved retailers can move quickly to implement our smart carts and begin realizing tangible benefits to their operations and improve the shopping experience for their customers.”About A2Z Cust2Mate Solutions Corp.A2Z Cust2Mate Solutions Corp. brings innovation, ease, excitement and value to retailers and shoppers. The Company is transforming brick-and-mortar retail with innovative smart shopping cart solutions that digitize the in-store shopping experience. The proven-in-use, friendly, sensor rich, AI driven carts enhance customer satisfaction and loyalty, minimize shrinkage, optimize retailers' operations and enable new business models. The smart carts streamline in-store shopping by enabling in-cart scanning and payment, allowing users to bypass checkout lines while alleviating labor shortages. Retailers can optimize merchandising, store layouts and promotions from data-driven insights, while shoppers get real-time information and personalized offers, turning a necessary chore into a fun and rewarding experience.For more information on A2Z Cust2Mate Solutions Corp. (NASDAQ:AZ)($AZ)(FRA - WKN:A3CSQ) and its subsidiary, Cust2mate Ltd., please visit, please visit www.cust2mate.com.Cautionary Statement Regarding Forward-looking StatementsMatters discussed in this press release may contain forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including whether the referenced patent will be granted. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the Company's filings on EDGAR and with the SEC. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. Forward-looking statements contained in this announcement are made as of this date, and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein.About NayaxNayax is a global commerce enablement, payments and loyalty platform designed to help merchants scale their business. Nayax offers a complete solution including localized cashless payment acceptance, management suite, and loyalty tools, enabling merchants to conduct commerce anywhere, at any time. As a global leader in serving unattended retail, Nayax has transformed into a comprehensive solution focused on our customers’ growth across multiple channels. As of June 30, 2024, Nayax has 11 global offices, approximately 1,100 employees, connections to more than 80 merchant acquirers and payment method integrations and is globally recognized as a payment facilitator. Nayax’s mission is to improve its customers’ revenue potential and operational efficiency. For more information, please visit www.nayax.com.Issued By: Swan Consultancy Sdn. Bhd. on behalf of A2Z Cust2mate Solutions Corp. and Nayax Ltd.For more information, please contact:Mandy TanEmail: m.tan@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.

ANKARA, Turkey, Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - GEN Pharmaceuticals (GENIL.IS), a leading Turkish pharmaceutical company, has announced the positive results of its Phase 2 clinical trial evaluating the safety and efficacy of its investigational drug, GN-037 topical cream, in treating mild to moderate plaque psoriasis. The findings were presented at Amsterdam's European Academy of Dermatology and Venereology (EADV) 2024 Congress.GEN PharmaceuticalsGEN Pharmaceuticals Manufacturing FacilityThis multicenter, randomized, double-blind, placebo-controlled Phase 2 study involved 190 patients across 19 clinical centers in Türkiye. Patients were treated with GN-037, clobetasol 17-propionate, or placebo twice daily for four weeks, followed by an additional four-week observation period. The study demonstrated GN-037's statistically significant superiority in reducing psoriasis symptoms compared to placebo, positioning it as a promising new treatment option for psoriasis patients worldwide.Key Findings:The GN-037 Phase 2 trial met the primary endpoint: treatment success,defined as the percentage of patients with at least a 2-grade improvement in Investigator's Global Assessment (IGA) score and achieving an IGA score of 0 or 1.37.9% of patients treated with GN-037 achieved treatment success at week four compared to 9.1% in the placebo group (P=0.006).GN-037 demonstrated significant improvements in reducing erythema (57.6%, P=0.008), plaque elevation (72.7%, P=0.001), and scaling (80.3%, P=0.006) compared to placebo.31.8% of patients in the GN-037 group achieved at least a 75% reduction in PASI, compared to 6.1% in the placebo group (P=0.009).No new safety concerns emerged with similar treatment-emergent adverse events across all arms.Abidin Gülmüs, Chairman of GEN, stated: "We are thrilled to announce the positive results of our Phase 2 clinical trial. We believe GN-037 offers new hope for the global psoriasis community."Nadir Ulu, MD, PhD, Vice President of R&D, added: "Our Phase 2 trial results highlighted GN-037's potential to improve patient outcomes significantly, and it may provide a novel, well-tolerated treatment option for patients with mild to moderate plaque psoriasis."About GEN:Founded in 1998, GEN is Türkiye's leading speciality pharmaceutical company. It is focused on developing innovative therapies across multiple therapeutic areas, with significant R&D investments and a commitment to advancing global healthcare. GEN actively works in both in-licensing and out-licensing business models. GEN partners with leading global pharmaceutical companies to bring innovative therapies and rare solutions to communities in its countries. It also develops and produces highly demanded and competitive therapeutic products in its GMP-certified manufacturing facility to bring therapy solutions required in international markets.For more information, visit www.genilac.com.tr.For inquiries:Bulutay GÜNES, Head of Corporate Brand, b.gunes@genilac.comAli KETENCIOGLU, Investor Relations Manager, a.ketencioglu@genilac.comContact InformationBulutay GunesHead of Corporate Brandb.gunes@genilac.comAli KetenciogluInvestor Relations Managera.ketencioglu@genilac.comSOURCE: GEN Pharmaceuticals Copyright 2024 ACN Newswire via SeaPRwire.com.

SELANGOR, Malaysia, Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - OSK Property is excited to announce its partnership with PeopleUp, a leading multi-enrichment and play group founded in 2018 in Singapore. Together, they will introduce a brand-new regional play brand to Atria Shopping Gallery in Petaling Jaya, marking PeopleUp’s FIRST expansion beyond Singapore. This groundbreaking entertainment hub will cater to families and kids, creating a one-stop destination for fun, learning, and holistic family experiences.1. Ong Ju Xing, Deputy Group Managing Director, OSK Holdings Berhad2. Samantha Lew Pey Shin, General Manager, Group Retail Leasing, OSK Property Investment3. Chris Tan Wei Quan, Chief Executive Officer, PeopleUp4. Loh Wai Keong, Managing Director & Chief Executive Officer, Greenwillow Capital Management[L-R]The signing ceremony took place at Atria Shopping Gallery and the agreement was executed between OSK Property Investment, Group Retail Leasing General Manager Samantha Lew Pey Shin and PeopleUp Singapore Chief Executive Officer Chris Tan Wei Quan. The event was witnessed by OSK Group Deputy Group Managing Director Ong Ju Xing and Greenwillow Capital Management Managing Director Loh Wai Keong.PeopleUp has successfully set its footprint in Malaysia, thanks to its regional strategic partners, Arkwood Trustee (M) Berhad and Greenwillow Capital Management. These two companies are backed by key figures, Sunny Yeo, Chief Executive Officer and Managing Director of Arkwood Trustee, and Loh Wai Keong, Managing Director of Greenwillow.With over 16 thriving subsidiary brands in Singapore, PeopleUp has earned its reputation for delivering innovative, engaging, and memorable experiences for families. Its flagship brands, such as Bouncy Paradise - Asia’s largest inflatable playground - and Dinoland - Singapore’s first immersive and largest indoor dinosaur park with live forest, along with VroomTown, the first mega indoor drive-play city for kids, have welcomed over half a million visitors annually.Set to open in the first half of 2025, the new expansion will build upon this success, showcasing exciting, family-oriented concepts from Singapore and introducing new experiences tailored to the Malaysian market.OSK Property Investment Group Retail Leasing General Manager Samantha Lew said "At OSK Property, we are committed to curating spaces that bring value and excitement to the community. Partnering with PeopleUp is an exciting step forward in transforming Atria Shopping Gallery into a choice destination for families. This new play concept will enhance the mall’s position as a leading family-friendly venue, attracting visitors from across the region."Chris Tan Wei Quan, Chief Executive Officer of PeopleUp Singapore, expressed his enthusiasm for the expansion: "We are thrilled to bring our unique, holistic approach of family entertainment to Malaysia. The collaboration with OSK Property allows us to share our vision and passion for innovative play and enrichment with a wider audience. We are confident that this flagship will resonate with families and set a new benchmark for family entertainment in the region."Anchoring over 60,000 square feet within Atria Shopping Gallery, PeopleUp will see the creation of an exciting new flagship family destination that encapsulates a wide array of fun, entertainment, and learning experiences. The flagship will bring together six key areas designed to cater to every type of play:Kids & Toddler Play: A safe and engaging environment for younger children to explore.Sports Play: Promoting active play and physical fitness through dynamic sports activities.E-gaming and Immersive Play: Combining cutting-edge technology with play for a thrilling digital experience.Sky Play: Adventure high above the ground with elevated play areas.Water Park: A fun-filled aquatic adventure for families.Special Experiences: Unique, curated experiences that will surprise and delight visitors.In addition to these fresh and exciting concepts, PeopleUp will also introduce its popular Singapore-based attractions to Atria Shopping Gallery, tailoring them to fit the tastes and preferences of the local market.These zones will offer an all-encompassing mix of physical, mental, and sensory experiences for children of all ages, the new flagship destination will set a new standard for family entertainment in Malaysia.OSK Property’s strategic partnership with PeopleUp is a testament to the growing demand for family-centric leisure destinations in Malaysia. By combining PeopleUp's award-winning concepts with OSK Property’s vision, Atria Shopping Gallery hopes to become the top destination for families seeking fun and enriching experiences.For more information, please visit Atria Shopping Gallery’s website at www.atria.com.my and PeopleUp Singapore's website at www.peopleup.com.sg About Atria Shopping GalleryAtria Shopping Gallery is a transformation of yesterday’s beloved iconic mall in Petaling Jaya to cater to today’s more sophisticated and discerning tastes. The Shopping Gallery’s beautiful interior is inspired by the natural beauty and exquisite forms found in our tropical rainforest, creating a sense of natural opulence and an ambience that is warm and welcoming. Atria strives to offer shoppers a total experience and has in place tenants, activities and an environment that we hope will leave our shoppers feeling relaxed, inspired and enriched.About the Developer – OSK PropertyOSK Property is the property arm of the OSK Group which is a public listed company in Malaysia with an asset size over RM 10 billion. OSK Property is one of Malaysia’s leading property groups that has completed and delivered more than 50,000 properties across Malaysia and Australia. With a diverse portfolio that spans residential, commercial, hospitality, industrial and mixed-use developments, OSK Property is committed to delivering innovative and engaging spaces that enhances the way of life of communities.With each project, OSK Property continues to seek and prioritize its sustainability strategy incorporating the integration of sustainable design features, minimizing our environmental footprint by incorporating advanced technologies and infusing the natural elements such as shadow play and wind flow, and utilizing environmentally friendly materials to ensure the overall health and well-being of occupants. For further information, visit OSK Property’s website at www.oskproperty.com.myIssued By: Swan Consultancy Sdn. Bhd. on behalf of OSK PropertyFor more information, please contact:Jazzmin WanTel: +60 17-289 4110Email: j.wan@swanconsultancy.bizAsyraf HakimiTel: +60 11-23774173Email: a.hakimi@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.

BOYERTOWN, Pa., Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - Global Advanced Metals (GAM), a leading global producer of metallurgical products, is pleased to announce a new partnership with the U.S. Department of Defense (DOD) to re-establish defense-critical niobium oxide production. The project, supported by a $26.4 million award from the Manufacturing Capability Expansion and Investment Prioritization directorate, leverages GAM's existing tantalum production in Boyertown, Pennsylvania.GAM LogoThe DOD's capital contribution will accelerate the development of the United States' first niobium oxide production in over 30 years. Niobium oxide is a precursor to high-purity superalloys in advanced aircraft, rocket systems, and various other defense platforms. GAM's public-private partnership forms a key component of the DOD's ongoing efforts to solidify the U.S. aerospace and defense industrial base."GAM is proud to contribute to strengthening U.S. and allied capability by mitigating supply vulnerabilities previously exploitable by our adversaries," said GAM's CEO, Andrew O'Donovan. "Every opportunity to decrease adversarial influence over defense supply chains should be taken, and we are delighted that the DOD chose to support GAM in this endeavor.""Pennsylvania has built and powered our Nation for generations, so it's no surprise that workers in Berks County will soon produce critical minerals to make the aircraft, rocket systems, and other equipment our military needs to ensure our national security," said U.S. Senator Bob Casey (D-PA). "I advocated for our Commonwealth to tackle this critical mineral risk so that we can continue the proud tradition of supporting our warfighters and the Department of Defense as a whole.""As a former chemistry teacher and Air Force officer, I've been championing efforts on critical mineral supply chains and the importance of bringing related manufacturing back to the U.S. since I first arrived in Congress," said U.S. Congresswoman Chrissy Houlahan (D-PA). "So when I visited Global Advanced Metals (GAM) in Berks County last year, I was in awe of their state-of-the-art operations - I knew GAM and companies like them have the blueprint we need to reduce reliance on countries like China for critical minerals. I'm so thrilled to hear GAM is receiving a $26.4 million award for niobium processing and manufacturing of defense-critical materials! With this federal investment, more jobs in our community will be created and our national security will be strengthened."About GAMA leading conflict-free tantalum producer, GAM has exclusive rights to the world's largest industrial resources of tantalum ore located in Western Australia.GAM produces conflict-free tantalum powders and metallurgical products at its Pennsylvania, USA and Aizu, Japan plants for a range of industries including electronics, aerospace, automotive, medical and chemical processing.GAM's smelting facilities in Japan and the USA were first declared "Conflict-Free" in 2010 under the former EICC/GeSI Conflict-Free Sourcing Initiative (CFSI) audit program and continue to maintain their conformance to the current Responsible Minerals Assurance Process (RMAP) standard.Contact InformationKurt HabeckerSr. Marketing Managerkhabecker@globaladvancedmetals.com1 610-369-8220SOURCE: Global Advanced Metals Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年9月24日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（"本公司"，連同其附屬公司統稱為"本集團"或"康哲藥業"）欣然宣佈，磷酸蘆可替尼乳膏（"蘆可替尼乳膏"或"產品"）（白癜風適應症）新藥上市許可申請（NDA）已於2024年9月24日獲得中國國家藥品監督管理局（NMPA）受理。這是產品繼白癜風適應症獲海南省藥監局批准臨床急需進口，及在澳門獲批上市等系列里程碑事件之後的又一重磅進展，也是邁出惠及中國逾千萬白癜風患者的關鍵一步。蘆可替尼乳膏在中國真實世界研究中取得了積極結果。治療組主要療效指標第24周達到F-VASI 75的患者比例為49.5%，顯著高於目標值14.1%（P

QUAKERTOWN, PA, Sept 24, 2024 - (ACN Newswire via SeaPRwire.com) - At the start of 2024, DEXIS introduced its digital ecosystem, a suite of tools and software designed to connect and streamline the implant workflow from diagnosis to delivery.Today, DEXIS announced upgrades across the ecosystem to aid clinicians in important workflow elements from visualizing progressive dental issues to designing chairside surgical guides."Our technology makes it easy to organize information and execute treatments, which is at the core of what clinicians expect from us," said DEXIS President, Robert Befidi. "We are connecting and standardizing the implant workflow while also constantly evaluating our efforts to ensure we provide deeper patient insights and flexible, intuitive solutions that reduce complexity. These three launches are a good example of our focus on continuous innovation across the ecosystem to deliver diagnostic confidence, productivity, and smart simplicity."A brand-new X-ray platform is now available, designed specifically for general practitioners looking to expand their diagnostic capabilities with 3D imaging. Developed and produced in Tuusula, Finland, the ORTHOPANTOMOGRAPH™ OP 3D™ EX captures consistently accurate images through a straightforward, easy-to-learn workflow. The unit has a wide range of field of view sizes to support multiple clinical indications, including implant placement, endodontics, periodontics, and analysis for airway and TMJ. Early adopters of the OP 3D EX have reported positive feedback:"When choosing a CBCT, the key factors for me were a large sensor, predictable acquisition, stellar image quality and intuitive software that wouldn't interrupt my workflow," says Dr. Tyler Tolbert of Smile Now Dental Group. "Once the OP 3D EX got here and we started taking some scans, I thought to myself, ‘We really made the right choice here!'"In addition to new hardware, a brand-new software release will provide advanced tools to plan and execute same-day, prosthetically driven implants.Serving as the unifying software and central hub of the ecosystem, DTX Studio™ Clinic stores and manages all patient data as well as helps clinicians execute each step of the implant process from diagnostics to delivery.The software's new functionality allows practitioners to plan an implant treatment and generate a surgical guide chairside - all in less than three minutes. Clinicians can virtually extract teeth, adjust photorealistic abutments and crowns, and create an automated surgical guide that can be sent to a lab or produced in-house for same-day delivery."We were able to implement the OP 3D EX quickly and start taking scans largely due to the included DTX Studio Clinic software," said Dr. Nicholas Varney of Varney Dental. "Once we got going, we found that so much of the work involved in prepping a 3D scan for confident diagnosis was done by the software automatically. DTX Studio Clinic has improved how we work in all aspects - communicating with patients, implant planning and even treatment team collaboration."In addition to 3D imaging enhancements, an intraoral scanning software update offers scan quality and usability improvements as well as clear visualizations of progressive dental issues over time, through a new tool called Oral Compare. Additionally, the software's new integration with SmileFy allows for the ability to simulate treatment outcomes chairside, giving patients further confidence in proposed treatment plans.To learn more about DEXIS and the latest implant workflow upgrades, visit https://www.dexis.com.About DEXISDEXIS is the global leader in dental imaging. We bring together the most trusted brands in 2D and 3D imaging, intraoral scanning solutions, and diagnostic software, in one connected and AI-powered ecosystem. Our innovative and award-winning technologies use smart simplicity to increase productivity and enhance diagnostic confidence. For more information, please visit dexis.com.About Envista Holdings CorporationEnvista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide array of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.Contact InformationMaria PenalozaMedia & Content Strategy Managermaria.penaloza@issuerdirect.comSOURCE: DEXIS Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, Sept 24, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). This is another substantial milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Products Administration and approval for marketing in Macau for vitiligo, and it is also a key step in benefiting over ten million of patients with vitiligo in China.Ruxolitinib cream achieved positive results in Chinese Real-World Study. The primary efficacy endpoint was the proportion of patients in the treatment group who achieved F-VASI 75 response at week 24, which was 49.5%, significantly higher than the target value of 14.1% (p